Rhumbline Advisers Kronos Bio, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 2,088 shares of KRON stock, worth $1,962. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,088
Previous 2,088
-0.0%
Holding current value
$1,962
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding KRON
# of Institutions
59Shares Held
20.7MCall Options Held
31.4KPut Options Held
0-
Vida Ventures Advisors, LLC2.77MShares$2.6 Million3.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$1.81 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.86MShares$1.75 Million0.0% of portfolio
-
Partners Capital Investment Group, LLP Boston, MA1.67MShares$1.57 Million0.04% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.35 Million0.11% of portfolio
About Kronos Bio, Inc.
- Ticker KRON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,769,100
- Market Cap $53.4M
- Description
- Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...